SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT – COMMERCIAL PRODUCT DRUG SUBSTANCEProduct Specific Agreement • July 25th, 2024 • Kiniksa Pharmaceuticals International, PLC • Pharmaceutical preparations
This Product Specific Agreement (this “PSA”) is made effective as of June 21, 2024 (the “PSA Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a private company organized under the laws of England and Wales with a Swiss branch office located at Grafenaustrasse 5, 6300 Zug, Switzerland (“Client”) and Samsung BioLogics Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and KINIKSA PHARMACEUTICALS (UK), LTD. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Such excluded information is not...Master Services Agreement • July 25th, 2024 • Kiniksa Pharmaceuticals International, PLC • Pharmaceutical preparations • New York
This Master Services Agreement (this “MSA”) is made and entered into as of June 21, 2024 (the “Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a private company organized under the laws of England and Wales with a Swiss branch office located at Grafenaustrasse 5, 6300 Zug, Switzerland (“Client”), and Samsung BioLogics Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
